Guest
A study of a closely-watched experimental Roche obesity pill has been tied to side effects, including nausea and vomiting, in a small study. The results raise questions for investors evaluating whether the novel medicine can compete with the next generation of weight loss drugs in a market expected to top $130 billion annually by the end of the decade. Sam Fazeli of Bloomberg Intelligence explains. Sign up for the Prognosis newsletter to get the latest in health, medicine and science — and what it means for you — from Bloomberg’s global team of health reporters. -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: Visit for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg Television on: X:
